Navigation Links
Dr. James F. Pingpank to Present at Leading Regional Therapies Conference

NEW YORK, Feb. 19 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP(TM)") System for the treatment of cancers of the liver, announced today that Dr. James F. Pingpank will present at The Fourth International Symposium on Regional Cancer Therapies, to be held February 21-23, 2009.

(Logo: )

Dr. Pingpank, Adjunct Principal Investigator of Delcath's Phase III Trial treating ocular and cutaneous melanoma metastatic to the liver, and Principal Investigator of the trial at the University of Pittsburgh Medical Center, will deliver two oral presentations titled:

       Impact of High-dose Melphalan (MEL) Administered via Hepatic Arterial
          Infusion for Patients with Unresectable Hepatic Metastases from
                              Neuroendocrine Tumors (MNET)


            Multi-institutional Clinical Trials in Regional Therapy for
                                 Liver Metastases

Commenting on the relevance of these topics, Richard L. Taney, President and CEO of Delcath Systems, stated, "As we move toward completion of our pivotal Phase III Trial, Dr. Pingpank's updates provide an invaluable communication to the other leaders in the field of regional cancer treatment. Dr. Pingpank and Dr. Marybeth Hughes, Principal Investigator of the Phase III Study at the National Cancer Institute, continue to show their dedication to the trial."

The Phase III Study

The Phase III clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. This clinical study is testing Delcath's PHP(TM) System for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath PHP System(TM) is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath PHP System(TM) or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System.

The Fourth International Symposium on Regional Cancer Therapies

The Fourth International Symposium on Regional Cancer Therapies will take place February 21-23, 2009 in Marco Island, Florida. The Symposium is sponsored by the David C. Koch Regional Cancer Therapy Center, the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences and UPMC Cancer Centers. The Koch Regional Cancer Therapy Center is committed to promoting research; development and application of regional cancer therapies; and exchanging information and promoting education among professionals regarding regional cancer therapies. More information on this conference can be found at

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company's intellectual property portfolio consists of twenty-seven patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
2. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
3. Hope for 14 Million Rosacea Sufferers: Pyratine-XR(TM) Study to be Presented at South Beach Symposium
4. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
5. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
6. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
7. EntreMed Presents Initial Clinical Results for ENMD-2076
8. Oridion Announces Significant Medical Studies Presented at STA
9. Pivotal Data Published For First Biomarker Combination Test to Determine Risk of Ovarian Cancer in Women Who Present With Pelvic Mass
10. Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015 Booth #4303 – The Imaging ... will exhibit a broader array of products in a new ... of North America in ... meeting will feature X-ray components "At the Heart of Imaging." ... of products from Varian,s Claymount brand, and computer-aided diagnostic software ...
(Date:11/30/2015)... EAST HANOVER, N.J. , Nov. 30, 2015 /PRNewswire/ ... and portfolio at the 57 th American Society ... across leukemias, lymphomas and myelomas as well as supportive ... populations, in addition to personalized cell therapies. The ASH ... Orlando, Florida . Novartis Oncology ...
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The presidential race normally deals ... So why is it a national news story when Donald Trump makes disparaging remarks ... because appearances count more than anyone wants to admit when it comes to how ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... a University of Delaware Accounting and Management of Information Systems course. Based in ... mid-market businesses. Sommer will speak at before student in the Enterprise Resource Planning ...
(Date:11/30/2015)... ... ... Cycling, running, and walking are regular Sunday activities for many South Floridians, but ... , That’s when the 7th annual ANF Group Tour de Broward will take ... at Joe DiMaggio Children’s Hospital. , The community fundraiser, sponsored by ANF ...
(Date:11/30/2015)... FL (PRWEB) , ... November 30, 2015 , ... ... a comparison chart and ingredient list of its hemorrhoid ointment to its website. ... effective pain relief for people suffering from hemorrhoids. Adding the comparison chart and ...
(Date:11/30/2015)... Plains, NJ (PRWEB) , ... November 30, 2015 , ... ... in a comfortable and convenient setting. , When you have dental problems, you need ... the field and can effectively diagnose and treat your needs, a friendly dentist who ...
Breaking Medicine News(10 mins):